Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,428.00    38.00 (1.59%)
Bid:
2,428.00
Ask:
2,430.00
Spread: 2.00 (0.082%)
Market Cap: £7.80b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

27 Jun 2024 07:00

RNS Number : 0367U
Bunzl PLC
27 June 2024
 

27 June 2024

 

 

BUNZL PRE-CLOSE STATEMENT

CONTINUED MARGIN GROWTH DRIVES PROFIT UPGRADE FOR FULL YEAR

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2024.

 

The Group is upgrading its guidance for the year based on improved margin performance, driven by good margin management, including increased own brand penetration, and acquisitions. The Group now expects to deliver robust revenue growth in 2024, at constant exchange rates, driven by acquisitions already completed in 2024; with a small decline in underlying revenue. Group operating margin is now expected to be slightly above the level reported for the full year 2023.

 

Group revenue in the first half is expected to decrease year-on-year by 3% to 4% at actual exchange rates and to decline by 0% to 1% at constant exchange rates. Underlying revenue, which is organic revenue adjusted for trading days, is expected to decline by around 5%, mainly driven by the previously disclosed volume reductions and deflation in our US business. Group operating margin for the first half of 2024 is expected to show a strong improvement compared to the first half of 2023, resulting in robust adjusted operating profit growth at constant exchange rates.

 

As expected, the decline in underlying revenue in North America in the first half of the year is driven by volume reductions in our US foodservice redistribution business, as we transition towards an increased own brand proposition; the ongoing impact from transitioning customer specific inventory in our US retail business; and deflation. Second quarter revenue trends in North America are expected to improve compared to the first quarter, with volumes starting to recover. We also expect a moderate decline in underlying revenue in Continental Europe and UK & Ireland, and some growth in Rest of the World. Good margin growth is expected in North America in the first half of the year and very strong margin growth in the UK & Ireland and Rest of the World. This is mainly due to the benefit from acquisitions and good ongoing margin management across the Group, following the strong margin performance in the second half of 2023.

 

In April, Bunzl signed an agreement to acquire RCL Implantes, a Brazilian distributor specialising in surgical and medical devices. This higher margin business generated revenue of BRL 112 million (c.£18 million) in 2023 and strengthens our position in this fragmented market. Competition authority clearance has now been received and the acquisition is expected to complete in the near future.

In June, Bunzl completed the acquisition of Clean Spot, a distributor of cleaning and hygiene products and equipment in Canada. The acquisition further enhances Bunzl's footprint in Canada and expands our product offering. In 2023 the business generated revenue of CAD 7 million (c. £4 million).

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Our agile and entrepreneurial teams continue to deliver robust profit growth. I am delighted with the ongoing successful margin management, including increasing penetration of own brands, demonstrated across the Group, allowing us to upgrade our full year profit outlook today. I am also pleased to welcome two more businesses to the Bunzl family, taking our total committed spend on acquisitions to around £600m so far this year. After an excellent start to the year for acquisitions, we maintain a strong balance sheet, providing us with significant optionality to continue to self-fund value-accretive acquisitions and our pipeline remains active."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLGDLLDDDGSL
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.